Guerbet Liver Fibrosis

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT06703450
Status
Enrolling By Invitation

Conditions

  • Metabolic Dysfunction-associated Steatotic Liver Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Accepted

Study Details

The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and blood tests in 50 initial patients with metabolic dysfunction-associated steatohepatitis (MASH).

Key Dates

First listed
Nov 25, 2024
Start date
Feb 28, 2024
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Participants with liver disease
    Participants with liver disease for diagnosis of liver fibrosis to have DCE-MRI

Primary Outcome Measure

Liver Stiffness by MR Elastography [ Time Frame: during procedure (MRI) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mount SinaiNew YorkNew York10029-

Find similar trials in New York, NY

By research site
Mount Sinai· New York, NY

Related Studies